Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Authors
Ying Cheng•David Spigel•Martijn Dorp
Journal
New England Journal of Medicine
Published
September 13, 2024
Abstract
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy.